Last updated: June 28, 2026
Executive summary
Pfizer sued Sun Pharma over alleged infringement of Pfizer patents tied to Pfizer’s branded product(s) in the asserted Orange Book family. The case is docketed in the District of New Jersey as 1:18-cv-01529. The litigation posture and the key infringement/validity issues turn on (i) whether Sun’s ANDA product (or proposed generic) infringes the asserted claims and (ii) Sun’s defenses including non-infringement, invalidity, and any statutory defenses tied to the timing of FDA approval and patent listing. The business consequence is straightforward: the outcome determines whether Sun can launch during the patent/market exclusivity window or is forced into a design-around, delayed entry, or license.
H1: Pfizer v. Sun 1:18-cv-01529 litigation summary, patents asserted, Paragraph IV issues, and generic entry risk
What is the case caption and what court is Pfizer v. Sun Pharmaceutical Industries Limited, 1:18-cv-01529 in?
Pfizer Inc. is the plaintiff and Sun Pharmaceutical Industries Limited is the defendant in case number 1:18-cv-01529 in the District of New Jersey.
Why this matters for ANDA and Orange Book disputes
A D.N.J. Hatch-Waxman case typically turns on:
- The asserted Orange Book-listed patents and their claim scope.
- Whether the defendant’s ANDA product infringes those claims.
- Whether asserted patents are invalid (written description, enablement, obviousness, anticipation, indefiniteness, etc.).
- Remedies, including injunctions and launch timing.
What patents does Pfizer assert against Sun in 1:18-cv-01529?
The litigation summary hinges on the specific asserted patent numbers and claim lists. Without the asserted-patent list and the complaint’s infringement mapping, a complete and accurate patent-level analysis cannot be produced.
What claims were likely litigated: composition, formulation, method-of-use, or manufacturing?
Hatch-Waxman complaints generally assert one or more of these categories:
- Composition claims (active ingredient identity and chemical form)
- Formulation claims (excipients, solid-state properties, dosage-form features)
- Method-of-use claims (indication-directed dosing regimens)
- Method-of-manufacture claims (process parameters)
A credible infringement analysis requires the asserted claim types and independent claim language from the complaint and claim charts. Those details are not available in the prompt.
What does the docket show about the timeline in Pfizer v. Sun (1:18-cv-01529)?
A litigation timeline should include, at minimum:
- complaint filing date
- answer and any counterclaims
- Markman schedule (if any)
- claim construction orders
- dispositive motions
- trial date (if applicable)
- settlement dates (if any)
- final judgment and appeal posture (if any)
Those docket dates are not provided, so a complete, date-anchored chronology cannot be stated.
What Paragraph IV defenses and non-infringement arguments are typically raised by Sun in this posture?
A Hatch-Waxman defendant commonly raises a bundle of defenses. Typical categories include:
- Non-infringement of each asserted claim based on ANDA paragraph certifications and product composition/process
- Invalidity based on prior art and legal standards
- Indefiniteness and lack of enablement
- Inequitable conduct or prosecution history estoppel (if supported)
- Statutory defenses tied to the patent term, exclusivity, or the scope of FDA exclusivity
A case-specific statement requires the actual defenses Sun pleaded in its answer, any counterclaims, and claim construction positions.
How do claim construction and Markman rulings affect outcomes in Pfizer v. Sun?
Claim construction can be outcome-determinative where patents cover:
- ranges (particle size, solubility, dissolution profiles)
- structural definitions (chemical moieties, salts, polymorphs)
- functional limitations (stability, bioavailability, release characteristics)
To analyze the effect in 1:18-cv-01529, the Markman order(s) and the construed terms must be identified from the docket or court filings. Those are not included in the request.
What is the litigation status: pending, dismissed, settled, or decided on the merits?
A correct status requires the most recent docket disposition (e.g., settlement order, dismissal without prejudice, summary judgment, final judgment, or appeal). The request does not provide any disposition or docket milestones.
Was there a settlement agreement in Pfizer v. Sun 1:18-cv-01529, and what was its practical impact?
Settlement analysis requires:
- whether the case settled pre-judgment
- the settlement’s key terms (launch date, design-around obligations, license scope, covenant not to sue)
- payment and consideration terms (if any), and whether FDA/ANDA timing was tied to settlement
Those terms are not provided.
What generic entry risk does Sun face if patents are not invalidated?
The generic entry risk is a function of:
- whether the asserted patents survive (validity upheld)
- whether infringement is found
- whether the court grants a permanent injunction or stays relief
- whether the NDA/ANDA product can launch during remaining exclusivity
A precise risk assessment requires the asserted patents’ expiration and the status of those patents (in suit, stayed, or stayed due to appeal). None of that information is present in the prompt.
What is the Orange Book status of the asserted patents for Sun’s ANDA product?
Orange Book status must be pulled from:
- patent listing numbers
- listed expiration dates
- patent use codes (e.g., drug substance, drug product, method of use)
- pediatric exclusivity or other granted exclusivities
- whether the defendant’s ANDA includes Paragraph IV certifications against particular patents
No Orange Book listing data is included.
When do Pfizer’s relevant patents and exclusivities expire in this litigation?
Expiration analysis requires:
- expiration dates for each asserted patent
- any regulatory exclusivity start and end dates
- whether later-granted patents extend market protection (subject to legal limitations)
No patent numbers or exclusivity periods are provided, so the exclusivity timeline cannot be computed.
How strong is the patent estate for Pfizer versus Sun’s likely design-around options?
Strength analysis requires claim-level features:
- whether patents are narrow or broad
- whether the claims are easy to avoid by changing salt form, polymorph, excipient, or dosing regimen
- whether method-of-use claims are enforceable against labeling
- whether the asserted claims map cleanly to the ANDA product composition/process
Without asserted claims and ANDA technical facts, strength and design-around feasibility cannot be stated.
How does this dispute compare with other Pfizer vs. generic manufacturer litigations?
Comparative analysis requires:
- similar Pfizer drug targets
- similar asserted patent families
- similar outcomes
No comparative anchor is provided.
What commercial exposure is at stake for Sun and Pfizer under a typical Hatch-Waxman outcome?
Commercial stakes depend on:
- branded annual sales tied to the product
- size of the ANDA market
- timing of FDA approval and expected launch dates
- probability of injunction vs. design-around vs. settlement
No sales or product identity is specified in the prompt.
Key Takeaways
- Case identity: Pfizer Inc. v. Sun Pharmaceutical Industries Limited, D.N.J. 1:18-cv-01529.
- What drives outcome: validity and infringement of the asserted Orange Book-listed patents, plus any settlement or dismissal terms affecting entry timing.
- What cannot be concluded from the provided input: the asserted patent numbers, claim categories, docket milestones, dispositive rulings, settlement terms, and Orange Book expiration dates.
FAQs
- What information in the complaint determines which patents Pfizer can enforce in 1:18-cv-01529?
- How does a Markman claim construction order typically change infringement analysis in Hatch-Waxman cases?
- What does an Android approval “Paragraph IV” certification mean for launch timing in a Pfizer v. Sun dispute?
- What are the usual remedies courts can award in ANDA patent infringement cases involving injunctions?
- How do settlement agreements in Hatch-Waxman cases practically affect FDA approval and generic launch dates?
References
No sources were provided in the request, and the necessary case-document specifics (complaint/answer/docket/Orange Book listings) are not included.
